NEW YORK (GenomeWeb News) – Qiagen will distribute a multiplex respiratory pathogen test manufactured by Celera, under an agreement announced today by the firms.
The molecular diagnostic test is the next-generation version of Qiagen's ResPlex II assay for detecting respiratory pathogens. The assay detects 19 different pathogens associated with respiratory infections and is designed for use on the LiquiChip 100 and 200 instrument platforms, which are based on Luminex's technology.
Under terms of the deal, Qiagen has exclusive worldwide rights to distribute the multiplex test kit, which Celera will manufacture. Qiagen expects to seek regulatory approval for the panel in the US and Europe.
"Celera's significant experience in the development and manufacturing of molecular diagnostic products is a very valuable resource and this relationship can accelerate our effort to further expand our molecular diagnostic solution portfolio," Qiagen CEO Peer Schatz said in a statement.
Financial and further terms of the agreement were not disclosed.